



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION



## PCSK9 (human, recombinant)


Item No. 20631

### Overview and Properties

<b>Synonyms:</b>	NARC-1, Proprotein Convertase Subtilisin Kexin 9
<b>Source:</b>	Active recombinant N-terminal His-tagged enzyme isolated from a HEK293 overexpression system
<b>Amino Acids:</b>	31-692
<b>Uniprot No.:</b>	Q8NBP7
<b>Molecular Weight:</b>	71 kDa (~16 & 63 kDa purified)
<b>Storage:</b>	-20°C (as supplied); avoid freeze/thaw cycles by aliquoting protein
<b>Stability:</b>	≥9 months
<b>Purity:</b>	≥95% estimated by SDS-PAGE
<b>Supplied in:</b>	Lyophilized from PBS, pH 7.4, with 30% sucrose
<b>Protein Concentration:</b>	Recommended reconstitution in serum-free media or sterile buffer to 200 µg/ml
<b>Activity:</b>	<b>batch specific</b> Qualitative biological assay - reduces uptake of LDL-DyLight™ by >30% in Huh7 cells at concentrations above 5 µg/ml


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Images



Lane 1: MW Markers  
Lane 2: PCSK9 (1 µg)  
Lane 3: PCSK9 (2 µg)

Representative gel image shown; actual purity may vary between each batch.



PCSK9 inhibits LDL uptake. On four separate plates Huh7 cells were plated and treated with or without 5 µg/ml PCSK9 in media. Sixteen hours later, LDL-DyLight™ 488 was added. After a four-hour incubation the cells were washed, trypsinized, and analyzed by flow cytometry.

WARNING  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/24/2021

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM

# PRODUCT INFORMATION



## Description

---

Proprotein convertase subtilisin kexin 9 (PCSK9) is a member of the subtilisin serine protease family with an important role in lipoprotein metabolism.<sup>1</sup> Mutation in the PCSK9 gene is associated with autosomal dominant hypercholesterolemia, which is characterized by an increase in low density lipoprotein (LDL) cholesterol levels.<sup>2</sup> PCSK9 overexpression in wild-type mice doubles the plasma total cholesterol, possibly through acceleration of the degradation of the LDL receptor.<sup>1,3</sup> PCSK9 mRNA is detected in various tissues such as liver, kidney, lung, spleen, jejunum, ileum, colon, and muscle, with the highest expression in the liver.<sup>4</sup> Human PCSK9 precursor is 692 amino acids in length with an estimated molecular weight of 74 kDa. This proprotein is self-cleaved to form a mature protein at around 63 kDa in the Golgi.<sup>5</sup> Cayman's PCSK9 (human, recombinant) contains the mature protein (~63 kDa) as well as the cleaved portion (~16 kDa).

## References

---

1. Maxwell, K.N., Fisher, E.A., and Breslow, J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. *Proc. Natl. Acad. Sci. USA* **102(6)**, 2069-2074 (2005).
2. Abifadel, M., Varret, M., Rabès, J.-P., *et al.* Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nature Genet.* **34(2)**, 154-156 (2003).
3. Maxwell, K.N. and Breslow, J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. *Proc. Natl. Acad. Sci. USA* **101(18)**, 7100-7105 (2004).
4. Seidah, N.G., Benjannet, S., Wickham, L., *et al.* The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. *Proc. Natl. Acad. Sci. USA* **100(3)**, 928-933 (2003).
5. Maxwell, K.N. and Breslow, J.L. Proprotein convertase subtilisin kexin 9: The third locus implicated in autosomal dominant hypercholesterolemia. *Curr. Opin. Lipidol.* **16**, 167-172 (2005).

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM